Biweekly THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for intermediate- and high-grade non-Hodgkin's lymphoma

Leukemia

Volumn 12, Issue 9, 1998, Pages 1457-1460

  Niitsu, N ^a   Umeda, M ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Granulocyte colony stimulating factor; International prognostic index; Non Hodgkin's lymphoma; Pirarubicin

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CYCLOPHOSPHAMIDE; GRANULOCYTE COLONY STIMULATING FACTOR; PIRARUBICIN; PREDNISONE; PROCARBAZINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CLINICAL ARTICLE; FEMALE; GRANULOCYTOPENIA; HUMAN; MALE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; SURVIVAL RATE; THROMBOCYTOPENIA;

EID: 0031665503     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401134     Document Type: Article

References (20)

1. Niitsu N, Umeda M. Biweekly COP-BLAM regimen combined with granulocyte colony-stimulating factor (C-CSF) for intermediate-grade non-Hodgkin's lymphoma. Eur J Haematol 1996; 56: 163-167.
2. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intern Med 1985; 102: 596-602.
3. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, Glick JH, Coltman CA Jr, Miller TP. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. New Engl J Med 1993; 328: 1002-1006.
4. Shipp MA. International non-Hodgkin's lymphoma prognostic factors project. A predictive model for aggressive non-Hodgkin's lymphoma. New Engl J Med 1993; 329: 987-994.
5. Tanosaki R, Okamoto S, Akatsuka N, ishida A, Michikawa N, Masuda Y, Uchida H, Murata M, Kizaki M, Ikeda Y. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma. Cancer 1994; 74: 1939-1944.
6. Ariyoshi Y, Ogawa M. Dose intensity in cancer chemotherapy. Jpn J Cancer Chemother 1994; 21: 2699-2707.
7. 123I-metaiodobenzylguanidine (MIBG) myocardial SPECT for cardiomyopathy due to adriamycin. Nucl Med Commun 1994; 31: 1051-1057.
8. Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.
9. Oken M, Creech R, Tormey D. Toxicity and response criteria of the Eastern Cooperative Oncology Croup. Am J Clin Oncol 1982; 5: 649-655.
10. The Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas; summary and description of working formulation for clinical usage. Cancer 1982; 49: 2112-2135.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observation. J Am Stat Assoc 1958; 53: 457-481.
12. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva, Switzerland: WHO, 1979.
13. Hryniuk WM, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984; 2: 1281-1288.
14. Goldie JH, Coldman AJ. A mathematics model for relating the directivity of tumors to their spontaneous mutation rate. Cancer Treat Res 1977; 63: 1727-1733.
15. Boyd DB, Coleman M, Papish SW, Topilow A, Kopel SK, Bernhardt B, Files JC, Schwartz S, Gaynor M, McDermott D. COPBLAM III: infusional combination chemotherapy for diffuse large cell lymphoma. J CLin Oncol 1988; 6: 425-433.
16. DeVita VT, SM Hubbard Jr, Longo DL. The chemotherapy of lymphoma - looking back moving forward: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 1987; 47: 5810-5824.
17. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma - results of a tree-structured survival analysis. J Clin Oncol 1990; 8: 963-977.
18. Temma K, Akera T, Chugun A, Kondo H, Hagane K, Hirano S. Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart. Eur J Pharmacol 1993; 234: 173-181.
19. Bastion Y, Blay JY, Divine M, Brise P, Bordessoule D, Sebban C, Michel B, Tilly H, Lederlin P, Deconinck E, Salles B, Dumontet C, Briere J, Coiffier B. Elderly patients with aggressive non-Hodgkin's lymphoma: disease presentation, response to treatment, and survival. A group d'etude des lymphomes de l'adulte study on 453 patients older than 69 years. J Clin Oncol 1997; 15: 2945-2953.
20. Niitsu N, Umeda M. THP-COPBLM (pirarubicin, cyclophosphamide, vincristine, prednisone, bleomycin and procarbazine) regimen combined with granulocyte colony-stimulating factor (G-CSF) for non-Hodgkin's lymphoma in elderly patients: a prospective study. Leukemia 1997; 11: 1817-1820.